Type of information: Nomination
Compound: member of the board of directors
Company: Allogene Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
- • On September 27, 2018, Allogene Therapeutics announced the appointment of Deborah M. Messemer to the company’s board of directors. Ms. Messemer has more than 30 years of experience providing financial expertise to public and private companies and was the Managing Partner of KPMG’s Bay Area and Northwest region until her recent retirement. Ms. Messemer, a certified public accountant (CPA), joined KPMG LLP, the U.S. member firm of KPMG International, in 1982 and was admitted into partnership in 1995. As Managing Partner for the Bay Area and Northwest region, she was responsible for leading over 3,000 team members in 10 offices across all functions, including audit, tax and advisory. Ms. Messemer spent the majority of her career in KPMG’s audit practice as an audit engagement partner serving public and private clients in a variety of industry sectors. In addition to audit signing
responsibilities, Ms. Messemer has significant experience in SEC filings, due diligence, initial public offerings, mergers and acquisitions, and internal controls over financial reporting.
Ms. Messemer was honored as the Financial Woman of the Year by the Financial Women of San Francisco (FWSF) in 2016 and was named as one of the Bay Area’s Most Influential
Women in Business by the San Francisco Business Times.
Ms. Messemer is a member of the National Association of Corporate Directors (NACD) and of the San Francisco Chapter of Women Corporate Directors (WCD). She has served extensively on non-profit and advisory boards including the Bay Area Council, the San Francisco Committee
on Jobs, the California Chamber of Commerce, the San Francisco Chamber of Commerce, the UC Berkeley Fisher Center Policy Advisory Board, San Francisco Ballet, and Posse. She is a member of the International Women’s Forum and Leadership San Francisco, Class of 2001.
- She received a bachelor’s degree in accounting from the University of Texas at Arlington.
- Allogene is advancing its AlloCAR T™ cell portfolio, which includes rights to 16 preclinical CAR T cell therapy targets and U.S. rights to UCART19, an AlloCAR T™ cell therapy candidate that is being developed for the treatment of CD19-expressing hematological malignancies. In partnership with Servier, UCART19 is in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).